newsfilter
← Latest News
GlobeNewswire·

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.Alignment with FDA on earlier ORIGIN 3 final